Have a question?
Please get in touch with our team in case of any queries
nn
m
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size | |
| Market Size | |
| CAGR | |
| Base Year | |
| Historic Year | |
| Forecast Year | |
| Market Segments | |
| Geographic Analysis | |
| Countries Covered |
This market research report on the global premature ejaculation therapeutics market offers analysis on market size & forecast, market share, industry trends, growth drivers, and vendor analysis. The market study also includes insights on segmentation by drug class (SSRIs, PDE5 inhibitors, anesthetic agents, and others), by ROA (oral therapeutics and topical therapeutics), and by geography (North America, Europe, APAC, Latin America, and MEA).
Premature Ejaculation Therapeutics Market - Overview
The increasing incidences of emotional and mental stress and other male sexual disorders, especially erectile dysfunction (ED) is fueling the growth of the global premature ejaculation therapeutics market. PE is the most prevalent sexual disorder among men across the globe. In recent years, the progress in medical research has increased the knowledge about several diseases to an in-depth level, thereby disclosing new target sites for drug treatment in the global market. The first oral drug was approved in 2009, and there are quite a few numbers of the drug under investigation for treating PE in the worldwide market. With the presence of a single approved oral premature ejaculation drug, the market regionally and globally is dominated by off-label drugs, generic versions of patent expired drugs and OTC formulations. The growing demand for various off-label and generic therapeutics will augment the growth of the global market over the next few years. The introduction of SSRIs and topical formulations is expected to revolutionize the market. Several vendors are offering off-label drugs that belong to different drug classes such as SSRIs, PDE5 inhibitors, and OTC topical creams/sprays for treating this disease. The increasing disease awareness, growing patient willingness to seek pharmaceutical therapy assistance for disease management, and the increasing presence of favorable guidelines that recommended the use of drugs as first-line therapy are the some of the major factors attributing to the growth of the global market. The increasing use of oral agents due to ease of use and absence of systemic side-effects will drive sales in the global premature ejaculation therapeutics market.
The entry of new vendors is leading to high capital investment for R&D activities and the manufacturing of new prescription drugs in the global market. The increasing awareness and focus on sexual wellness will create lucrative opportunities for leading vendors operating in the market. The global premature ejaculation therapeutics market is estimated to reach revenues of approximately $3 billion by 2024, growing at a CAGR of around 9% during 2018-2024.
Premature Ejaculation Therapeutics Market – Dynamics
The growing emphasis on the clinical progress of love hormones receptor antagonists is driving the growth of the global premature ejaculation therapeutics market. The existence of unmet demand is encouraging the progress of scientific research to understand better disease pathophysiology as certain novel drug targets and to innovate novel molecules with better efficacy and safety in the global market. The growing focus on the development of new molecules, which can inhibit the CNS neurotransmitter, oxytocin is also known as the love hormone will lead to the launch of new products in the market. Recent scientific researches result in the discovery of the involvement of oxytocin in central and peripheral oxytocinergic neurotransmission in the ejaculatory process. Several clinical trials and pre-clinical studies suggest the potential for highly selective oxytocin receptor antagonists in the treatment of PE. The pipeline studies of these drugs with oxytocin receptor antagonists will create the high potential to gain regulatory approval and access for the treatment in the global premature ejaculation therapeutics market during the forecast period.
Premature Ejaculation Therapeutics Market – Segmentation
This market research report includes a detailed segmentation of the market by drug class, ROA, and geography.
Premature Ejaculation Therapeutics Market – By Drug Class
The efficacy and safety of SSRIs will boost the demand for these drugs in the global premature ejaculation therapeutics market
The global premature ejaculation therapeutics market by drug class is segmented into SSRIs, PDE5 inhibitors, anesthetic agents, and others. SSRIs segment dominated more than 1/3rd of the total market share in 2018, growing at a CAGR of more than 8% during the forecast period. SSRIs is the most common type of drug for premature ejaculation treatment, and the introduction of Priligy (dapoxetine), which gained regulatory approval in 2009 is fueling the growth of this segment in the global market. According to multiple pre-clinical and clinical studies, alternation of the physiological activity of these 5-HT receptors with the antidepressant selective serotonin reuptake inhibitors (SSRIs) results in delayed ejaculation. The multiple evidence-based clinical trials that offer satisfactory efficacy and safety of SSRIs is contributing to the sale of these therapeutics in the global market. A recent survey conducted in the US indicated that 71% of the urologists prescribed an SSRI as the initial management of PE. The increasing pattern of healthcare professionals' recommendation of SSRIs will contribute to the growth of the global premature ejaculation therapeutics market.
Some of the common brand names of PDE5 inhibitors that are available in the global market include Cialis, Viagra, and Levitra. The plethora of unlicensed formulations, comprising anesthetic drugs and anesthetic agents will lead to an increase in clinical trials in the market. The other drugs that are available in the global premature ejaculation therapeutics market are opioid-based analgesics, alpha-blockers, beta-adrenergic blockers, TCAs, and SNRIs.
Premature Ejaculation Therapeutics Market – By ROA
Minimal risk of systemic adverse effects of topical drugs will boost sales in the global premature ejaculation therapeutics market
The ROA segment in the global premature ejaculation therapeutics market is classified into oral therapeutics and topical therapeutics. Topical therapeutics is the fastest growing segment in the global market, at a CAGR of over 10% during the forecast period. The continual approval for new topical OTC formulations, rise in product uptake of existing products due to increase in disease awareness, and interest of couples for sexual wellbeing are some of the factors attributing to the growth of this segment in the global market. The different varieties of topical formulations available in the global market include formulations include creams, gels, sprays, powders, emulsion, solutions, and ointments. Most of the topical PE drug formulations are amide anesthetics, which comprise lidocaine, benzocaine or a combination of lidocaine and prilocaine. The increasing availability of these products as OTC drugs and can be purchased without physicians' prescription is driving the demand for these products in the global market. These drugs offer improved ease of use and are associated with minimal/no systemic adverse events thereby, boosting sales in the global premature ejaculation therapeutics market.
The presence of a wide range of drugs recommended by physicians for the management of this condition is contributing to the demand for oral therapeutics in the global market. The daily dose oral therapies can exhibit improved and enhanced efficacy over topical therapies for treating PE. Some of the leading off-label oral formulation brands available in the global premature ejaculation therapeutics market are Viagra, Cialis, Zoloft, Paxil, Prozac, Levitra, and Lexapro.
Premature Ejaculation Therapeutics Market – By Geography
The launch of a large variety of OTC drugs across North America will contribute to the growth of the global premature ejaculation therapeutics market
The global premature ejaculation therapeutics market by geography is categorized into North America, Europe, APAC, Latin America, and MEA. North America occupied the largest market share in 2018, growing at a CAGR of around 9% during the forecast period. The rising lifestyle-related stress, the rise in chronic conditions, which can lead to the incidence of PE, increases in cancers, especially prostate cancer is fueling the growth of the North American region in the global market. The increased awareness and various public and private sponsored health campaigns will boost the demand for innovative therapeutics in the North America market. The advent of new drugs and increasing availability of OTC drugs will contribute to the growing sales in the North American region. The increasing interest in sexual health and wellness will create lucrative opportunities for leading vendors across the North America region in the global premature ejaculation therapeutics market.
Germany, the UK, France, Italy, and Spain are the primary revenue contributors across the European region in the global market. The high disease prevalence population, improvement in healthcare spending, increase in PE awareness, increase in uptake of PE drugs especially the off-label generic medicines, and low-cost OTC drugs are fueling the demand across the APAC region in the global premature ejaculation therapeutics market.
The key countries profiled in the report are:
- US
- Canada
- UK
- Germany
- France
- Italy
- Spain
- Japan
- India
- China
- Australia
- Brazil
- Mexico
Key Vendor Analysis
The global premature ejaculation therapeutics market is fairly fragmented due to the presence of pharma companies and generic manufacturers. The top vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents to attract the maximum number of consumers in the global market. The exponential growth of the APAC and Latin American region will create lucrative investment opportunities for prominent players in the market. Factors such as access to drugs, high disease awareness, and high affordability will help companies boost revenues in the global premature ejaculation therapeutics market.
The major vendors in the global market are:
- Absorption Pharmaceuticals
- INNOVUS PHARMACEUTICALS
- Pfizer
- Plethora Solutions Holdings
Other prominent vendors include Bayer, Eli Lilly and Company, GlaxoSmithKline, Recordati, Royalty Pharma, The Menarini Group, Ixchelsis and NeuroHealing Pharmaceuticals
Key market insights include
- The analysis of global premature ejaculation therapeutics market provides market size and growth rate for the forecast period 2019-2024.
- It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global premature ejaculation therapeutics market.
- The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
- It offers a complete overview of market segments and the regional outlook of global premature ejaculation therapeutics market.
- The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.
SNAPSHOT
The global premature ejaculation therapeutics market size is expected to reach revenues of approximately $3 billion by 2024, growing at a CAGR of around 9% 2018–2024.
The global premature ejaculation therapeutics market is driven by growing patient willingness to seek pharmaceutical therapy assistance for disease management. The launch of off-label drugs belonging to SSRIs and topical formulations will revolutionize the global market over the next few years. The market research report provides in-depth market analysis and segmental analysis of the global premature ejaculation therapeutics market by drug class, ROA, and geography.
Base Year: 2018
Forecast Year: 2019–2024
The report considers the present scenario of the global premature ejaculation therapeutics market and its market dynamics for the period 2019−2024. It covers a detailed overview of various market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes the leading companies and various other prominent companies operating in the market.
Major Vendors in the Global Premature Ejaculation Therapeutics Market
- Absorption Pharmaceuticals
- Business Overview
- Major Product Offerings
- Key Strategies
- Key Strengths
- Key Opportunities
- INNOVUS PHARMACEUTICALS
- Pfizer
- Plethora Solutions Holdings
Prominent Players in the Global Premature Ejaculation Therapeutics Market
- Bayer
- Business Overview
- Major Product Offerings
- Key Assessment
- Key Assessment
- Key Assessment
- Eli Lilly and Company
- GlaxoSmithKline
- Recordati
- Royalty Pharma
- The Menarini Group
- Ixchelsis
- NeuroHealing Pharmceuticals
Market Segmentation by Drug Class
- SSRIs
- PDE5 Inhibitors
- Anesthetic Agents
- Others
Market Segmentation by ROA
- Oral Therapeutics
- Topical Therapeutics
Market Segmentation by Geography
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- APAC
- Japan
- India
- China
- Australia
- Latin America
- Brazil
- Mexico
- MEA
Frequently Asked Questions
List of Exhibits
Exhibit 1 Segmentation of Global Premature Ejaculation Therapeutics Market
Exhibit 2 Market Size Calculation Approach 2018
Exhibit 3 Broader Classification of PE
Exhibit 4 Differentiation of Symptoms in Different PE Sub-types
Exhibit 5 Common Causative Factors for PE
Exhibit 6 PE Prevalence Rate across Geographies
Exhibit 7 ISSN Recommended Drug Classes for PE Treatment
Exhibit 8 PE Treatment Algorithm
Exhibit 9 Key Considerations of PE Clinical Trials
Exhibit 10 Key Primary/Secondary Endpoints in PE Clinical Trials
Exhibit 11 Key Hurdles in Research and Innovation of Breakthrough PE Drugs
Exhibit 12 Prevalence Rate of PE in Different Regions (%)
Exhibit 13 Number of Men with Premature Ejaculation in US and EU (Million)
Exhibit 14 Comparison of Prevalence Rates of PE and Erectile Dysfunction (ED) in Different Groups (%)
Exhibit 15 Increase in Global Diabetes Prevalence by Region 2015–2040 (Million)
Exhibit 16 Increase in Global ED Prevalence 1995−2025 (million)
Exhibit 17 Increase in Global Prostate Cancer Incidence by Region 2012–2020 (thousand)
Exhibit 18 Popular Therapeutics Available for PE Treatment in Market
Exhibit 19 PE OTC Drugs Marketing Channels
Exhibit 20 Major Drawbacks of Non-pharmacological PE Treatments
Exhibit 21 Number of Men with Premature Ejaculation 2018 (Million)
Exhibit 22 Major Factors Restricting PE Treatment Rate
Exhibit 23 Korean Country-wide Survey Results 0n Urologists' PE Treatment Rates Per Week in 2012 (%)
Exhibit 24 Popular Alternative PE Treatment Methods
Exhibit 25 Key Challenges Leading to Clinical Trial Terminations/Withdrawals
Exhibit 26 Global Premature Ejaculation Therapeutics Market 2018–2024 ($ million)
Exhibit 27 Five Forces Analysis 2018
Exhibit 28 Global Premature Ejaculation Therapeutics Market by Drug Class
Exhibit 29 Market by Drug Class 2018 & 2024 (%)
Exhibit 30 Market by Drug Class CAGRs (2018−2024)
Exhibit 31 Market by Drug Class 2018−2024 ($ million)
Exhibit 32 Common SSRIs for Treating PE
Exhibit 33 Comparison of Varying Efficacy Rates of Off-label SSRIs
Exhibit 34 Mode of Action of SSRIs
Exhibit 35 Global Premature Ejaculation Therapeutics Market by SSRIs 2018–2024 ($ million)
Exhibit 36 Major PDE5i Drug Brands as Off-label PE Medications
Exhibit 37 Global PE Therapeutics Market by PDE5 Inhibitors 2018–2024 ($ million)
Exhibit 38 Common Active Ingredients in Topical Anesthetic Formulations
Exhibit 39 Global PE Therapeutics Market by Anesthetic Agents 2018–2024 ($ million)
Exhibit 40 Several Other Drug Classes Used for Treating Premature Ejaculation
Exhibit 41 Market by Other Drug Classes 2018–2024 ($ million)
Exhibit 42 Market by ROA 2018 & 2024 (%)
Exhibit 43 Market by ROA 2018−2024 ($ million)
Exhibit 44 Market by ROA 2018−2024 (%)
Exhibit 45 Major Oral Therapeutics Recommended for PE
Exhibit 46 Benefits/Drawbacks Summary of Oral PE Drugs
Exhibit 47 Global Oral Premature Ejaculation Therapeutics Market 2018–2024 ($ million)
Exhibit 48 Available Topical Forms of PE Topical Therapies
Exhibit 49 Benefits/Drawbacks Summary of Topical PE Drugs
Exhibit 50 Global Topical Premature Ejaculation Therapeutics Market 2018–2024 ($ million)
Exhibit 51 Global Market: Share of Various Regions 2018 & 2024 (%)
Exhibit 52 Global Market by Geography CAGRs (2018−2024)
Exhibit 53 Global Market by Geography 2018−2024 ($ million)
Exhibit 54 Global Market by Geography 2018−2024 (%)
Exhibit 55 PE Therapeutics Market in North America 2018 (%)
Exhibit 56 Market in North America 2018–2024 ($ million)
Exhibit 57 Market in North America by Key Countries 2018 & 2024
Exhibit 58 Market in US 2018–2024 ($ million)
Exhibit 59 Market Segmentation in US by Drug Class 2018 (%)
Exhibit 60 Market in US by SSRIs 2018−2024 ($ million)
Exhibit 61 Market in US by PDE5 Inhibitors 2018−2024 ($ million)
Exhibit 62 Market in US by Anesthetic Agents 2018−2024 ($ million)
Exhibit 63 Market in Canada 2018–2024 ($ million)
Exhibit 64 PE Therapeutics Market Segmentation in Canada by Drug Class 2018 (%)
Exhibit 65 Market in Canada by SSRIs 2018−2024 ($ million)
Exhibit 66 Market in Canada by PDE5 Inhibitors 2018−2024 ($ million)
Exhibit 67 Market Canada by Anesthetic Agents 2018−2024 ($ million)
Exhibit 68 Key premature Therapeutic Ejaculation Market Dynamics
Exhibit 69 Market in Europe by Country 2018
Exhibit 70 Market in Europe 2018–2024
Exhibit 71 Prevalence Trend of Prostate Cancer Holding High Associated Risk for PE Incidence in Europe 2012–2020 (thousand)
Exhibit 72 PE Therapeutics Market in Europe by Key Countries 2018 & 2024
Exhibit 73 Market in Germany 2018–2024 ($ million)
Exhibit 74 Market Segmentation in Germany by Drug Class 2018 (%)
Exhibit 75 PE Therapeutics Market in Germany by SSRIs 2018−2024 ($ million)
Exhibit 76 Market in Germany by PDE5 Inhibitors 2018−2024 ($ million)
Exhibit 77 Market in Germany by Anesthetic Agents 2018−2024 ($ million)
Exhibit 78 PE Therapeutics Market in UK 2018–2024 ($ million)
Exhibit 79 PE Therapeutics Market in UK by SSRIs 2018−2024 ($ million)
Exhibit 80 Market in UK by PDE5 Inhibitors 2018−2024 ($ million)
Exhibit 81 Market in UK by Anesthetic Agents 2018−2024 ($ million)
Exhibit 82 Premature Ejaculation Therapeutics Market in France 2018–2024 ($ million)
Exhibit 83 Premature Ejaculation Therapeutics Market Segmentation in France by Drug Class 2018 (%)
Exhibit 84 Premature Ejaculation Therapeutics Market in France by SSRIs 2018−2024 ($ million)
Exhibit 85 Premature Ejaculation Therapeutics Market in France by PDE5 Inhibitors 2018−2024 ($ million)
Exhibit 86 Premature Ejaculation Therapeutics Market in France by Anesthetic Agents 2018−2024 ($ million)
Exhibit 87 Premature Ejaculation Therapeutics Market in Italy 2018–2024 ($ million)
Exhibit 88 Premature Ejaculation Therapeutics Market Segmentation in Italy by Drug Class 2018 (%)
Exhibit 89 Premature Ejaculation Therapeutics Market in Italy by SSRIs 2018−2024 ($ million)
Exhibit 90 Premature Ejaculation Therapeutics Market in Italy by PDE5 Inhibitors 2018−2024 ($ million)
Exhibit 91 Premature Ejaculation Therapeutics Market in Italy by Anesthetic Agents 2018−2024 ($ million)
Exhibit 92 Premature Ejaculation Therapeutics Market in Spain 2018–2024 ($ million)
Exhibit 93 Premature Ejaculation Therapeutics Market Segmentation in Spain by Drug Class 2018 (%)
Exhibit 94 Premature Ejaculation Therapeutics Market in Spain by SSRIs 2018−2024 ($ million)
Exhibit 95 Premature Ejaculation Therapeutics Market in Spain by PDE5 Inhibitors 2018−2024 ($ million)
Exhibit 96 Premature Ejaculation Therapeutics Market in Spain by Anesthetic Agents 2018−2024 ($ million)
Exhibit 97 Key Premature Therapeutic Ejaculation Market Dynamics
Exhibit 98 Premature Ejaculation Therapeutics Market in APAC by Country 2018 (%)
Exhibit 99 Premature Ejaculation Therapeutics Market in APAC 2018–2024 ($ million)
Exhibit 100 Premature Ejaculation Therapeutics Market in APAC by Key Countries 2018 & 2024
Exhibit 101 Premature Ejaculation Therapeutics Market in Japan 2018–2024 ($ million)
Exhibit 102 Market Segmentation in Japan by Drug Class 2018 (%)
Exhibit 103 Premature Ejaculation Therapeutics Market in Japan by SSRIs 2018–2024 ($ million)
Exhibit 104 Premature Ejaculation Therapeutics Market in Japan by PDE5 Inhibitors 2018–2024 ($ million)
Exhibit 105 Premature Ejaculation Therapeutics Market in Japan by Anesthetic Agents 2018–2024 ($ million)
Exhibit 106 Premature Ejaculation Therapeutics Market in India 2018–2024 ($ million)
Exhibit 107 Premature Ejaculation Therapeutics Market Segmentation in India by Drug Class 2018 (%)
Exhibit 108 Premature Ejaculation Therapeutics Market in India by SSRIs 2018–2024 ($ million)
Exhibit 109 Premature Ejaculation Therapeutics Market in India by PDE5 Inhibitors 2018–2024 ($ million)
Exhibit 110 Premature Ejaculation Therapeutics Market in India by Anesthetic Agents Inhibitors 2018–2024 ($ million)
Exhibit 111 Premature Ejaculation Therapeutics Market in China 2018–2024 ($ million)
Exhibit 112 Premature Ejaculation Therapeutics Market Segmentation in China by Drug Class 2018 (%)
Exhibit 113 Market in China by SSRIs 2018–2024 ($ million)
Exhibit 114 PE Therapeutics Market in China by PDE5 inhibitors 2018–2024 ($ million)
Exhibit 115 Market in China by Anesthetic Agents 2018–2024 ($ million)
Exhibit 116 Market in Australia 2018–2024 ($ million)
Exhibit 117 Premature Ejaculation Therapeutics Market Segmentation in Australia by Drug Class 2018 (%)
Exhibit 118 Premature Ejaculation Therapeutics Market in Australia by SSRIs 2018–2024 ($ million)
Exhibit 119 Premature Ejaculation Therapeutics Market in Australia by PDE5 Inhibitors 2018–2024 ($ million)
Exhibit 120 Market in Australia by Anesthetic Agents 2018–2024 ($ million)
Exhibit 121 Key Premature Therapeutic Ejaculation Market Dynamics
Exhibit 122 Premature Ejaculation Therapeutics Market in Latin America by Country 2018 (%)
Exhibit 123 Market in Latin America 2018–2024 ($ million)
Exhibit 124 Market in Brazil 2018–2024 ($ million)
Exhibit 125 Market Segmentation in Brazil by Drug Class 2018 (%)
Exhibit 126 Market in Brazil by SSRIs 2018–2024 ($ million)
Exhibit 127 PE Therapeutics Market in Brazil by PDE5 Inhibitors 2018–2024 ($ million)
Exhibit 128 Market in Brazil by Anesthetic Agents 2018–2024 ($ million)
Exhibit 129 Market in Mexico 2018–2024 ($ million)
Exhibit 130 Market Segmentation in Mexico by Drug Class 2018 (%)
Exhibit 131 Market in Mexico by SSRIs 2018–2024 ($ million)
Exhibit 132 Market in Mexico by PDE5 Inhibitors 2018–2024 ($ million)
Exhibit 133 Premature Ejaculation Therapeutics Market in Mexico by Anesthetic Agents 2018–2024
Exhibit 134 Key Premature Therapeutic Ejaculation Market Dynamics
Exhibit 135 Market in MEA 2018–2024 ($ million)
Exhibit 136 Key Premature Therapeutic Ejaculation Market Dynamics
Exhibit 137 Strategic Recommendations for Market Participants
Exhibit 138 INNOVUS PHARMACEUTICALS: Product Offerings
Exhibit 139 GlaxoSmithKline: Product Offerings
List of Tables
Table 1 Key Geographies Definition
Table 2 Key Caveats
Table 3 Currency Conversion 2013−2018
Table 4 Popular Definitions of Premature Ejaculation
Table 5 Summary of PE Epidemiology Studies
Table 6 Recommended/Optional Questions to Establish Diagnosis and Treatment of PE
Table 7 Summary of PE Validated Questionnaires
Table 8 Summary of Commonly Recommended PE Drugs
Table 9 Key Pipeline PE Drug Molecules
Table 10 Epelsiban: Product Profile
Table 11 IX-01 Product Profile
Table 12 DA-8031 Product Profile
Table 13 Key Dormant/Terminated/Withdrawn PE Pipeline Drug Molecules
Table 14 Major Unmet Need in PE Market
Table 15 YOY Impact of Market Growth Enablers 2018−2024
Table 16 YOY Impact of Market Growth Enablers on Regions 2018
Table 17 Key Terminated/Withdrawn and Inactive Investigational PE Drugs
Table 18 YOY Impact of Market Growth Restraints 2018−2024
Table 19 YOY Impact of Market Growth Restraints on Regions 2018
Table 20 Marketed PE Drugs with Meter-Dose Delivery Systems
Table 21 Pipeline Oxytocin Receptor Antagonists
Table 22 YOY Impact of Market Opportunities & Trends 2018−2024
Table 23 YOY Impact of Market Opportunities & Trends on Regions 2018
Table 24 Commonly Used Topical PE OTC Ester/Amide Anesthetic
Table 25 Key Topical Therapy PE Drugs by Type of Formulation
Table 26 Comparison of Popular Topical Anesthetics for PE
Table 27 Key PE Campaigns Launched in Europe
Table 28 Competitive Structure Analysis of Global Premature Ejaculation Therapeutics Market 2018
Table 29 Absorption Pharmaceuticals: Product Offerings
Table 30 Therapeutic Area and Products of INNOVUS PHARMACEUTICALS
Table 31 Pfizer: Product Offerings
Table 32 Plethora Solutions Holdings: Product Offerings
Table 33 Bayer: Product Offerings
Table 34 Eli Lilly and Company’s Human Pharmaceutical Products Segment: Major Products
Table 35 Eli Lilly and Company’s Animal Health Products Segment: Major Products
Table 36 Eli Lilly and Company: Product Offerings
Table 37 Recordati: Product Offerings
Table 38 Royalty Pharma: Product Offerings
Table 39 The Menarini Group: Product Offerings
Table 40 Qualitative Summary of Global Premature Ejaculation Therapeutics Market
Table 41 Global Premature Ejaculation Therapeutics Market by Geographies 2018–2024 ($ million)
Table 42 Global Premature Ejaculation Therapeutics Market by Drug Class Types 2018–2024 ($ million)
Table 43 Global Premature Ejaculation Therapeutics Market by ROA Types 2018–2024 ($million)
1 Research Methodology
2 Research Objectives
3 Research Process
4 Report Coverage
4.1 Market Definition
4.2 Base Year
4.3 Scope of Study
4.3.1 Market Segmentation by Product Types
4.3.2 Market Segmentation by ROA
4.3.3 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Premature Ejaculation: An Overview
7.1.1 Premature Ejaculation Definition
7.1.2 Disease Overview
7.1.3 Classification of Premature Ejaculation
7.1.4 Symptoms of PE
7.1.5 Aetiology of Premature Ejaculation
7.1.6 Epidemiology
8 ISSN Guidelines on Premature Ejaculation
8.1 Disease Assessment
8.1.1 Patient History
8.1.2 Physical Examination
8.1.3 Assessment Instruments
8.2 Treatment Options for PE
8.2.1 Physiological Therapy
8.2.2 Behavioral Techniques
8.2.3 Pharmacological Treatment
9 Clinical Trial Landscape
9.1 Overview
9.1.1 Subjects Selection Criteria for PE Clinical Trials
9.1.2 Clinical Trial Data Evaluation Considerations
9.1.3 Clinical Trial Design Considerations for PE
9.2 Clinical Trial EndPoints
10 Pipeline Landscape
10.1 Overview
10.2 Key Pipeline Drug Candidates
10.3 Key Pipeline Molecules
10.3.1 Epelsiban
10.3.2 IX-01
10.3.3 DA-8031
10.4 Dormant/Terminated/Withdrawn Drug Candidates
11 Market Dynamics
11.1 Market Growth Enablers
11.1.1 Increase in the Prevalence of PE and Other Chronic Diseases in Men
11.1.2 Wide Accessibility to PE OTC Drugs and Generic Off-label Drugs
11.1.3 Low-effectiveness of Non-pharmacological PE Treatment
11.1.4 Presence of High Unmet Demand
11.1.5 YOY Impact of Market Growth Enablers
11.1.6 Impact of Market Growth Enablers on Regions
11.2 Market Growth Restraints
11.2.1 Low Treatment Seeking Patient Pool
11.2.2 Presence of Alternative PF Treatment Methods
11.2.3 Clinical Trial Withdrawals/Terminations and Inactive Clinical Studies
11.2.4 Associated Adverse Effects of PE Drugs
11.2.5 YOY Impact of Market Growth Restraints
11.2.6 Impact of Market Growth Restraints on Regions
11.3 Market Opportunities & Trends
11.3.1 Advances in PE Drug Formulation Technology
11.3.2 Emphasis on Clinical Progress of Love Hormone Receptor Antagonists
11.3.3 Increased Awareness Campaigns and Initiatives for PE Treatment
11.3.4 YOY Impact of Market Opportunities & Trends
11.3.5 Impact of Market Opportunities & Trends on Regions
12 Global Premature Ejaculation Market
12.1 Market Overview
12.2 Market Size & Forecast
12.3 Porter’s Five Forces Analysis
12.3.1 Threat of New Entrants
12.3.2 Bargaining Power of Suppliers
12.3.3 Bargaining Power of Buyers
12.3.4 Threat of Substitutes
12.3.5 Competitive Rivalry
13 By Drug Class
13.1 Market Overview
13.2 SSRIs
13.2.1 Market Overview
13.2.2 Market Size & Forecast
13.3 PDE5 Inhibitors
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Anesthetic Agents
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Others
13.5.1 Market Overview
13.5.2 Market Size & Forecast
14 By Route of administration
14.1 Market Overview
14.2 Oral Therapeutics
14.2.1 Market Overview
14.2.2 Market Size & Forecast
14.3 Topical Therapeutics
14.3.1 Market Overview
14.3.2 Market Size & Forecast
15 By Geography
15.1 Market Overview
16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.4 US: Market Size & Forecast
16.4.1 Segmentation by Drug Class
16.4.2 SSRIs: Market Size & Forecast
16.4.3 PDE5 Inhibitors: Market Size & Forecast
16.4.4 Anesthetic Agents: Market Size & Forecast
16.5 Canada: Market Size & Forecast
16.5.1 Segmentation by Drug Class
16.5.2 SSRIs: Market Size & Forecast
16.5.3 PDE5 Inhibitors: Market Size & Forecast
16.5.4 Anesthetic Agents: Market Size & Forecast
16.6 Key Trend, Enablers, and Restraints
17 Europe
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.4 Germany: Market Size & Forecast
17.4.1 Segmentation by Drug Class
17.4.2 SSRIs: Market Size & Forecast
17.4.3 PDE5 Inhibitors: Market Size & Forecast
17.4.4 Anesthetic Agents: Market Size & Forecast
17.5 UK: Market Size & Forecast
17.5.1 Segmentation by Drug Class
17.5.2 SSRIs: Market Size & Forecast
17.5.3 PDE5 Inhibitors: Market Size & Forecast
17.5.4 Anesthetic Agents: Market Size & Forecast
17.6 France: Market Size & Forecast
17.6.1 Segmentation by Drug Class
17.6.2 SSRIs: Market Size & Forecast
17.6.3 PDE5 Inhibitors: Market Size & Forecast
17.6.4 Anesthetic Agents: Market Size & Forecast
17.7 Italy: Market Size & Forecast
17.7.1 Segmentation by Drug Class
17.7.2 SSRIs: Market Size & Forecast
17.7.3 PDE5 Inhibitors: Market Size & Forecast
17.7.4 Anesthetic Agents: Market Size & Forecast
17.8 Spain: Market Size & Forecast
17.8.1 Segmentation by Drug Class
17.8.2 SSRIs: Market Size & Forecast
17.8.3 PDE5 Inhibitors: Market Size & Forecast
17.8.4 Anesthetic Agents: Market Size & Forecast
17.9 Key Trend, Enablers, and Restraints
18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.4 Japan: Market Size & Forecast
18.4.1 Segmentation by Drug Class
18.4.2 SSRIs: Market Size & Forecast
18.4.3 PDE5 Inhibitors: Market Size & Forecast
18.4.4 Anesthetic Agents: Market Size & Forecast
18.5 India: Market Size & Forecast
18.5.1 Premature Ejaculation Therapeutics Market in India: Segmentation by Drug Class
18.5.2 SSRIs: Market Size & Forecast
18.5.3 PDE5 Inhibitors: Market Size & Forecast
18.5.4 Anesthetic Agents: Market Size & Forecast
18.6 China: Market Size & Forecast
18.6.1 Segmentation by Drug Class
18.6.2 SSRIs: Market Size & Forecast
18.6.3 PDE5 Inhibitors: Market Size & Forecast
18.6.4 Anesthetic Agents: Market Size & Forecast
18.7 Australia: Market Size & Forecast
18.7.1 Segmentation by Drug Class
18.7.2 SSRIs: Market Size & Forecast
18.7.3 PDE5 Inhibitors: Market Size & Forecast
18.7.4 Anesthetic Agents: Market Size & Forecast
18.8 Key Trends, Enablers, and Restraints
19 Latin America
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.4 Brazil: Market Size & Forecast
19.4.1 Segmentation by Drug Class
19.4.2 SSRIs: Market Size & Forecast
19.4.3 PDE5 Inhibitors: Market Size & Forecast
19.4.4 Anesthetic Agents: Market Size & Forecast
19.5 Mexico: Market Size & Forecast
19.5.1 Segmentation by Drug Class
19.5.2 SSRIs: Market Size & Forecast
19.5.3 PDE5 Inhibitors: Market Size & Forecast
19.5.4 Anesthetic Agents: Market Size & Forecast
19.6 Key Trends, Enablers, and Restraints
20 Middle-East & Africa
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Trends, Enablers, and Restraints
21 Competitive Landscape
21.1 Market overview
21.2 Strategic Recommendations for Market Participants
22 Key Company Profiles
22.1 Absorption Pharmaceuticals
22.1.1 Business Overview
22.1.2 Major Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 Innovus Pharmaceuticals
22.2.1 Major Product Offerings
22.2.2 Key Strengths
22.2.3 Key Strategies
22.2.4 Key Opportunities
22.3 Pfizer
22.3.1 Business Overview
22.3.2 Major Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 Plethora Solutions Holdings
22.4.1 Business Overview
22.4.2 Major Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
23 Other Prominent Vendors
23.1 Bayer
23.1.1 Business Overview
23.1.2 Product Offerings
23.1.3 Key Strengths
23.1.4 Key Strategies
23.1.5 Key Opportunities
23.2 Eli Lilly and Company
23.2.1 Business Overview
23.2.2 Product Offerings
23.2.3 Key Strengths
23.2.4 Key Strategies
23.2.5 Key Opportunities
23.3 GlaxoSmithKline
23.3.1 Business Overview
23.3.2 Product Offerings
23.3.3 Strength Assessment
23.3.4 Strategy Assessment
23.3.5 Opportunity Assessment
23.4 Recordati
23.4.1 Business Overview
23.4.2 Product Offerings
23.4.3 Key Strengths
23.4.4 Key Strategies
23.4.5 Key Opportunities
23.5 Royalty Pharma
23.5.1 Business Overview
23.5.2 Product Offerings
23.5.3 Key Strengths
23.5.4 Key Strategies
23.5.5 Key Opportunities
23.6 The Menarini Group
23.6.1 Business Overview
23.6.2 Product Offerings
23.6.3 Key Strengths
23.6.4 Key Strategies
23.6.5 Key Opportunities
23.7 Ixchelsis
23.7.1 Key Strengths
23.7.2 Key Strategy
23.7.3 Key Opportunity
23.8 NeuroHealing Pharmaceuticals Inc.
23.8.1 Key Strength
23.8.2 Key Strategy
23.8.3 Key Opportunity
24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
24.3 Qualitative Summary
24.4 Quantitative Summary
24.4.1 Market by Geography
24.4.2 Market by Drug Class
24.4.3 Market by ROA
25 Appendix
25.1 Abbreviations
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts